CA2360020A1 - Methods for differentiating and monitoring parathyroid and bone status related diseases - Google Patents

Methods for differentiating and monitoring parathyroid and bone status related diseases Download PDF

Info

Publication number
CA2360020A1
CA2360020A1 CA002360020A CA2360020A CA2360020A1 CA 2360020 A1 CA2360020 A1 CA 2360020A1 CA 002360020 A CA002360020 A CA 002360020A CA 2360020 A CA2360020 A CA 2360020A CA 2360020 A1 CA2360020 A1 CA 2360020A1
Authority
CA
Canada
Prior art keywords
parathyroid hormone
level
whole
peptide fragment
inhibitory peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002360020A
Other languages
French (fr)
Other versions
CA2360020C (en
Inventor
Thomas L. Cantor
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scantibodies Laboratory Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30770665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2360020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2360020A1 publication Critical patent/CA2360020A1/en
Application granted granted Critical
Publication of CA2360020C publication Critical patent/CA2360020C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Abstract

The present invention relates to novel methods and devices for differentiati ng in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non- fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.

Claims (46)

1. A method for differentiating between a person having substantially normal parathyroid function and having hyperparathyroidism comprising determining and comparing at least two of the parameters selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and the total parathyroid hormone level in the person.
2. The method of Claim 1 wherein the comparison is in the form of a ratio or proportion.
3. The method of Claim 1 wherein the person is a patient with chronic uremia.
4. The method of Claim 1 wherein one measures the whole parathyroid hormone level and the total parathyroid hormone level in the person, determines the parathyroid hormone inhibitory peptide fragment level from these two measurements, and compares the whole parathyroid hormone level to the parathyroid hormone inhibitory peptide fragment level.
5. The method of Claim 4 wherein the comparison is in the form of a ratio or proportion.
6. The method of Claim 4 wherein the person is a patient with chronic uremia.
7. A method for differentiating between a person having substantially normal parathyroid function and having hyperparathyroidism comprising determining one parameter selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and a calculated total parathyroid hormone level.
8. The method of Claim 7 wherein one determines the parathyroid hormone inhibitory peptide fragment level by measuring the whole parathyroid hormone level and the total parathyroid hormone level.
9 The method of Claim 7 wherein one determines the total parathyroid hormone level by measuring the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
10. The method of Claim 7 wherein the person is a patient with chronic uremia.
11. The method of Claim 1 wherein one measures and compares the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
12. The method of Claim 11 wherein the comparison is in the form of a ratio or proportion.
13. The method of Claim 11 wherein the person is a patient with chronic uremia.
14. The method of Claim 1 wherein one measures and compares the whole parathyroid hormone level and the total parathyroid hormone level in the person.
15. The method of Claim 14 wherein the comparison is in the form of a ratio or proportion.
16. The method of Claim 14 wherein the person is a patient with chronic uremia.
17. The method of Claim 1 wherein one measures and compares the parathyroid hormone inhibitory peptide fragment level and the total parathyroid hormone level in the person.
18. The method of Claim 17 wherein the comparison is in the form of a ratio or proportion.
19. The method of Claim 17 wherein the person is a patient with chronic uremia.
20. A method for monitoring parathyroid related bone diseases and treatments therefor comprising determining and comparing at least two of the parameters selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and the total parathyroid hormone level in the person.
21. The method of Claim 20 wherein the comparison is in the form of a ratio or proportion.
22. The method of Claim 20 wherein one measures the whole parathyroid hormone level and the total parathyroid hormone level in the person, determines the parathyroid hormone inhibitory peptide fragment level from these two measurements, and compares the whole parathyroid hormone level to the parathyroid hormone inhibitory peptide fragment level.
23. The method of Claim 22 wherein the comparison is in the form of a ratio or proportion.
24. The method of Claim 20 wherein one measures and compares the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
25. The method of Claim 20 wherein one measures and compares the whole parathyroid hormone level and the total parathyroid hormone level in the person.
26. The method of Claim 24 wherein the comparison is in the form of a ratio or proportion.
27. The method of Claim 25 wherein the comparison is in the form of a ratio or proportion.
28. The method of Claim 20 wherein one measures and compares the parathyroid hormone inhibitory peptide fragment level and the total parathyroid hormone level in the person.
29. The method of Claim 28 wherein one measures the whole parathyroid hormone level in order to calculate the parathyroid hormone inhibitory peptide fragment level from the whole parathyroid hormone level and the total parathyroid hormone level.
30. The method of Claim 28 wherein the comparison is in the form of a ratio or proportion.
31. A method for monitoring parathyroid related bone diseases and treatments therefor comprising determining one parameter selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and the calculated total parathyroid hormone level.
32. The method of Claim 31 wherein one determines the parathyroid hormone inhibitory peptide fragment level by measuring the whole parathyroid hormone level and the total parathyroid hormone level.
33. The method of Claim 31 wherein one determines the total parathyroid hormone level by measuring the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
34. A method for monitoring the effects of therapeutic treatment for hyperparathyroidism comprising determining and comparing at least two of the parameters selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and the total parathyroid hormone level in the person.
35. The method of Claim 34 wherein the comparison is in the form of a ratio or proportion.
36. The method of Claim 34 wherein one measures the whole parathyroid hormone level and the total parathyroid hormone level in the person, determines the parathyroid hormone inhibitory peptide fragment level from these two measurements, and compares the whole parathyroid hormone level to the parathyroid hormone inhibitory peptide fragment level.
37. The method of Claim 36 wherein the comparison is in the form of a ratio or proportion.
38. The method of Claim 34 wherein one measures and compares the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
39. The method of Claim 34 wherein one measures and compares the whole parathyroid hormone level and the total parathyroid hormone level in the person.
40. The method of Claim 39 wherein the comparison is in the form of a ratio or proportion.
41. The method of Claim 34 wherein one determines and compares the parathyroid hormone inhibitory peptide fragment level and the total parathyroid hormone level in the person.
42. The method of Claim 41 wherein one determines the parathyroid hormone inhibitory fragment level by measuring the whole parathyroid hormone and the total parathyroid hormone level.
43. The method of Claim 41 wherein the comparison is in the form of a ratio or proportion.
44. A method for monitoring the effects of therapeutic treatment for hyperparathyroidism comprising determining one parameter selected from the group consisting of the whole parathyroid hormone level, the parathyroid hormone inhibitory peptide fragment level, and the calculated total parathyroid hormone level.
45. The method of Claim 44 wherein one determines the parathyroid hormone inhibitory peptide fragment level by measuring the whole parathyroid hormone level and the total parathyroid hormone level.
46. The method of Claim 44 wherein one determines the total parathyroid hormone level by measuring the whole parathyroid hormone level and the parathyroid hormone inhibitory peptide fragment level.
CA2360020A 1999-01-14 2000-01-13 Methods for differentiating and monitoring parathyroid and bone status related diseases Expired - Fee Related CA2360020C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/231,422 US6689566B1 (en) 1999-01-14 1999-01-14 Methods, kits, and antibodies for detecting parathyroid hormone
US09/344,639 1999-06-26
US09/344,639 US6743590B1 (en) 1999-01-14 1999-06-26 Methods for differentiating and monitoring parathyroid and bone status related diseases
US09/231,422 1999-06-26
PCT/US2000/000855 WO2000042437A1 (en) 1999-01-14 2000-01-13 Methods for differentiating and monitoring parathyroid and bone status related diseases

Publications (2)

Publication Number Publication Date
CA2360020A1 true CA2360020A1 (en) 2000-07-20
CA2360020C CA2360020C (en) 2012-03-20

Family

ID=30770665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2360020A Expired - Fee Related CA2360020C (en) 1999-01-14 2000-01-13 Methods for differentiating and monitoring parathyroid and bone status related diseases

Country Status (8)

Country Link
US (6) US6689566B1 (en)
EP (2) EP1151307B1 (en)
JP (1) JP4132677B2 (en)
AT (1) ATE354803T1 (en)
CA (1) CA2360020C (en)
DE (1) DE60033499T2 (en)
ES (1) ES2277827T3 (en)
WO (1) WO2000042437A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) * 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
GB9927125D0 (en) * 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
DE19961350A1 (en) * 1999-12-17 2001-06-21 Immundiagnostik Ag Method for determining parathyroid activity in a human sample
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
DE10116552A1 (en) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Method for determining the effective parathyroid hormone activity in a sample
US20030082179A1 (en) * 2001-07-03 2003-05-01 Hutchison James Scott Parathyroid hormone antibodies and related methods
US7056655B2 (en) * 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
KR100540659B1 (en) * 2003-07-02 2006-01-10 삼성전자주식회사 Method and apparatus for printing enlarged image, and computer-readable recording media for storing computer program
WO2005007218A2 (en) * 2003-07-11 2005-01-27 Euro-Celtique S.A. Ex vivo perfusion
BR0318454A (en) * 2003-08-08 2006-09-12 Abgenix Inc parathyroid hormone (pth) targeting antibodies and their uses
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20050170443A1 (en) * 2003-10-03 2005-08-04 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
US7541140B2 (en) * 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment
US20060115430A1 (en) * 2004-10-27 2006-06-01 Cantor Thomas L Calcium challenge test for detecting calcium homeostasis disorders
KR100621096B1 (en) * 2005-02-01 2006-09-13 삼성전자주식회사 Method and apparatus for correcting systematic error using magnetic field
US7959920B2 (en) * 2005-09-06 2011-06-14 Scantibodies Laboratory, Inc. Methods of making and using antibodies directed to parathyroid hormone
EP1952151B1 (en) * 2005-11-04 2013-01-02 Novartis Vaccines and Diagnostics S.r.l. Rapid elisa
US8012694B2 (en) * 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
US20100021496A1 (en) * 2008-04-15 2010-01-28 Cantor Thomas L Methods, kits, and antibodies for quantitative determination of parathyroid hormone molecules with intact c-terminus
WO2012058292A2 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents Parathyroid hormone variants and assays related to disease
WO2012147021A1 (en) * 2011-04-28 2012-11-01 Koninklijke Philips Electronics N.V. Evaluating assays which optical inhomogeneities
EP2775306B1 (en) 2013-03-08 2018-06-27 Immundiagnostik AG Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
WO2016109378A1 (en) 2014-12-29 2016-07-07 North Carolina State University Multiplexed diagnostic to recognize concentrations of related proteins and peptides
EP3740762A1 (en) 2018-01-17 2020-11-25 Immundiagnostik AG Biomarker predicting coronary artery disease
CN114184796A (en) * 2021-12-03 2022-03-15 广州达泰生物工程技术有限公司 Kit and method for quantitatively detecting full-segment parathyroid hormone

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26839A (en) 1860-01-17 Valorus drew
US47686A (en) 1865-05-09 Improved gang-plow
US94704A (en) 1869-09-14 Improved mode of preserving wood
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5599774A (en) * 1979-01-26 1980-07-30 Semiconductor Res Found Electrostatic induction type thyristor
DK159276C (en) * 1980-03-31 1991-02-18 Takeda Chemical Industries Ltd PROCEDURE FOR THE ISOLATION OF SPECIFIC ANTIBODIES AND ENZYM IMMUNE DETERMINATION METHOD USING THE ISOLATED ANTIBODY
US4369138A (en) 1980-07-15 1983-01-18 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4508828A (en) 1983-03-21 1985-04-02 Immuno Nuclear Corporation Bioassay of parathyroid hormone
US4851356A (en) * 1983-05-06 1989-07-25 The Trustees Of Columbia University In The City Of New York Immunoassay for human chorionic gonadotropin
FR2550204B1 (en) 1983-08-05 1987-11-13 Toyo Jozo Kk PEPTIDE DERIVATIVES OF (NLE8, NLE1B, TYR34) -H-PTH
DE3346953A1 (en) * 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg CARDIODILATIN, A NEW PEPTIDE HORMONE AND METHOD FOR THE PRODUCTION THEREOF
JPS60136596A (en) * 1983-12-26 1985-07-20 Suntory Ltd Peptide and diuretic comprising it as active ingredient
DE3347548A1 (en) 1983-12-30 1985-07-11 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Agent and method for the specific immunological determination of the C-terminal fragment 68-84 of parathyroid hormone
US5026653A (en) * 1985-04-02 1991-06-25 Leeco Diagnostic, Inc. Scavenger antibody mixture and its use for immunometric assay
JP2598801B2 (en) * 1986-07-18 1997-04-09 ザ ユニバーシティー オブ メルボルン Malignant-PTHrP active protein in humoral hypercalcemia
WO1988009376A1 (en) * 1987-05-20 1988-12-01 Genentech, Inc. Method and compositions for making acsf and acsf antagonists
US4824777A (en) * 1987-07-08 1989-04-25 Ciba Corning Diagnostics Corp. Method for determining thyroxine uptake
US5075218A (en) * 1987-12-29 1991-12-24 Biomira, Inc. Screening for antibodies which bind carbohydrate epitopes of tumor-associated antigens, and uses thereof
DK172110B1 (en) * 1988-04-15 1997-10-27 Gen Hospital Corp Method for Isolating Mutants of DNA Sequences and Their Use in Identifying Cell Surface Proteins
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (en) 1989-10-27 1991-05-08 Forssmann Wolf Georg DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
JPH04132677A (en) 1990-09-25 1992-05-06 Union Material Kk Production of thin plate-shaped single crystal by melt-pressure method
US5256543A (en) * 1991-05-10 1993-10-26 Sangstat Medical Corporation HLA typing
US5208041A (en) * 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
DE4203040A1 (en) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh NEW PARATHORMON FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2141588A1 (en) 1992-08-05 1994-02-17 Sandra R. Hilliker Parathyroid hormone fragments and analogs
DE4227454C1 (en) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Process for early detection, for the detection of the severity as well as for the therapy-accompanying assessment of the course of sepsis as well as means for carrying out the process
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
DE4434551A1 (en) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptides from the sequence of hPTH (1-37)
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5744128A (en) * 1995-05-03 1998-04-28 Holick; Michael F. Use of emu oil for stimulating skin and hair growth
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5792455A (en) * 1996-03-21 1998-08-11 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody vaccines
JP3607430B2 (en) * 1996-08-28 2005-01-05 東レ・ダウコーニング・シリコーン株式会社   Method for producing powdered silicone cured product
US5858712A (en) 1997-02-06 1999-01-12 Incyte Pharmaceuticals, Inc. CDNA encoding a LEA-motif developmental protein homologous to avian px19
WO1998051337A2 (en) 1997-05-12 1998-11-19 Aphton Corporation Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
CA2306344A1 (en) * 1997-10-14 1999-04-22 Masahiko Sato Method of building and maintaining bone
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US6689566B1 (en) * 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6923968B2 (en) * 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US6867177B2 (en) * 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
DE19961350A1 (en) 1999-12-17 2001-06-21 Immundiagnostik Ag Method for determining parathyroid activity in a human sample
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP3401564B2 (en) * 2000-07-31 2003-04-28 独立行政法人産業技術総合研究所 Condensing light emitting device with integrated light source
US20030138858A1 (en) * 2000-08-10 2003-07-24 Cantor Thomas L Methods and devices for direct determination of cyclase inhibiting parathyroid hormone
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
US7226749B2 (en) * 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US6838264B2 (en) * 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US20030082179A1 (en) * 2001-07-03 2003-05-01 Hutchison James Scott Parathyroid hormone antibodies and related methods
WO2003009804A2 (en) * 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US6553637B1 (en) * 2001-10-22 2003-04-29 Ang-Yu Chen Movable buckle structure
US6524788B1 (en) * 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en) * 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
EP1578354A4 (en) * 2002-03-26 2008-04-09 Massachusetts Inst Technology Targets, methods, and reagents for diagnosis and treatment of schizophrenia
US20040018556A1 (en) 2002-07-29 2004-01-29 Cantor Thomas L. Reagent and method for determination of a substance using an immunoaggregator
US20040067526A1 (en) * 2002-10-03 2004-04-08 Cantor Thomas L. Methods for diagnosing and guiding treatment of bone turnover disease
JP4541899B2 (en) 2003-01-24 2010-09-08 ザ ジェネラル ホスピタル コーポレイション Conformationally restricted parathyroid hormone (PTH) analogs with lactam bridges
US20050025839A1 (en) 2003-07-28 2005-02-03 Polli James Edward Formulation approach to enhance transporter-mediated drug uptake
US7459276B2 (en) * 2003-09-29 2008-12-02 Scantibodies Laboratory, Inc. Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
US7465703B1 (en) * 2003-10-01 2008-12-16 Scantibodies Laboratory, Inc. Methods and kits useful for guiding osteoporosis related therapy
US20050170443A1 (en) * 2003-10-03 2005-08-04 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
US20050202506A1 (en) * 2004-03-11 2005-09-15 Cantor Thomas L. Methods for identifying and producing specific amino acid dependent antibodies and uses thereof
US7541140B2 (en) 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
EP1893142B1 (en) * 2005-05-09 2013-04-24 Cook Medical Technologies LLC Intragastric device for treating obesity
US7959920B2 (en) * 2005-09-06 2011-06-14 Scantibodies Laboratory, Inc. Methods of making and using antibodies directed to parathyroid hormone

Also Published As

Publication number Publication date
US6743590B1 (en) 2004-06-01
EP1729135A2 (en) 2006-12-06
DE60033499D1 (en) 2007-04-05
EP1729135A3 (en) 2008-07-02
EP1151307A4 (en) 2003-01-02
US20110300642A1 (en) 2011-12-08
EP1151307A1 (en) 2001-11-07
US20050095631A1 (en) 2005-05-05
ES2277827T3 (en) 2007-08-01
US7892749B2 (en) 2011-02-22
CA2360020C (en) 2012-03-20
US20040185536A1 (en) 2004-09-23
US8470543B2 (en) 2013-06-25
US7723042B2 (en) 2010-05-25
WO2000042437A1 (en) 2000-07-20
DE60033499T2 (en) 2007-12-06
JP2002535622A (en) 2002-10-22
EP1151307B1 (en) 2007-02-21
US7943323B2 (en) 2011-05-17
US6689566B1 (en) 2004-02-10
JP4132677B2 (en) 2008-08-13
US20040229281A1 (en) 2004-11-18
ATE354803T1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CA2360020A1 (en) Methods for differentiating and monitoring parathyroid and bone status related diseases
Olsen Arm and leg paresis as outcome predictors in stroke rehabilitation.
Allen et al. Muscle performance, voluntary activation and perceived effort in normal subjects and patients with prior poliomyelitis
Keller et al. Effects of indomethacin on bone ingrowth
Mori et al. How does deep breathing affect office blood pressure and pulse rate?
DE60028358D1 (en) HMG1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION
Croucher et al. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease
WO2003103697A3 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
DE60037816T2 (en) PHARMACEUTICAL FORMULATION CONTAINING MEGALATRANE AND ITS PRO-PHARMAKA
WO1995024650A3 (en) Methods of diagnosing and treating preeclampsia
WO2005018413A3 (en) Methods, kits and antibodies for detecting parathyroid hormone
Imura et al. Postoperative ambulatory level after hip fracture in the elderly predicts survival rate
Widimský Jr et al. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus
Samson et al. Effects of ear plugging on single-unit azimuth sensitivity in cat primary auditory cortex. II. Azimuth tuning dependent upon binaural stimulation
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
WO2002048136A1 (en) Keratinocyte proliferation inhibitors
Italian-Belgian Isradipine Study Group Multicenter evaluation of the safety and efficacy of isradipine in hypertension
WO2004031727A3 (en) Methods for diagnosing bone turnover disease
D'Avanzo et al. Update of trends in mortality from stroke in Italy from 1955 to 1987
Nott et al. Changes in the protein expression of hedgehog and patched-1 in perisutural tissues induced by cranial distraction
Oster et al. Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks
Lopushinsky et al. Regional variation in surgery for gastroesophageal reflux disease in Ontario
Mondal et al. A2693 Variation of blood pressure with nature of job among Bangladeshi subjects
Xiaolei et al. A2698 Relation of Serum Uric Acid to Asymptomatic Proximal Extracranial Artery Stenosis in a Middle-Aged Chinese Population
Chao et al. A8489 Associations of Life-course Body Mass Index Trajectories with Blood Pressure in Adulthood: A 30-year follow-up study

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150113